fetching data ...

SAT0430 (2020)
SECUKINUMAB EFFECTIVENESS IN 1543 PATIENTS WITH PSORIATIC ARTHRITIS TREATED IN ROUTINE CLINICAL PRACTICE IN 13 EUROPEAN COUNTRIES IN THE EuroSpA RESEARCH COLLABORATION NETWORK
B. Michelsen1, S. Georgiadis1, D. DI Giuseppe1, A. G. Loft1, M. Nissen1, F. Iannone1, M. Pombo-Suarez1, H. Mann1, Z. Rotar1, K. Eklund1, T. K. Kvien1, M. J. Santos1, B. Gudbjornsson1, C. Codreanu1, S. Yilmaz1, J. K. Wallman1, C. H. Brahe1, B. Moeller1, E. G. Favalli1, C. Sánchez-Piedra1, L. Nekvindova1, M. Tomsic1, N. Trokovic1, E. Kristianslund1, H. Santos1, T. Love1, R. Ionescu1, Y. Pehlivan1, G. T. Jones1, I. Van der Horst-Bruinsma1, L. Midtbøll Ørnbjerg1, M. Ǿstergaard1, M. L. Hetland1
1EuroSpA Research Collaboration Network, Copenhagen, Denmark

Background: There is a lack of real-life evidence on secukinumab effectiveness in psoriatic arthritis (PsA) patients.


Objectives: To assess the real-life 6- and 12-month secukinumab retention rates and proportions of patients in remission/low disease activity (LDA) overall, and by prior biologic disease-modifying anti-rheumatic drug (bDMARD)/targeted synthetic (ts)DMARD use.


Methods: Data from PsA patients treated with secukinumab in routine care from 13 countries in the European Spondyloarthritis (EuroSpA) Research Collaboration Network were pooled. Patients started secukinumab ≥12 months before date of datacut. Crude and LUNDEX adjusted (crude value adjusted for drug retention) 28-joint Disease Activity index for PSoriatic Arthritis (DAPSA28) and 28-joint Disease Activity Score with CRP (DAS28CRP) remission and LDA rates were calculated. Group comparisons between b/tsDMARD naïve, 1 prior and ≥2 prior b/tsDMARD users were done with ANOVA, Kruskal-Wallis, Chi-square or Kaplan-Meier analyses with log-rank test, as appropriate.


Results: A total of 1543 PsA patients were included ( Table 1 ). b/tsDMARD naïve patients had shorter time since diagnosis, higher baseline disease activity, a higher proportion were men and a higher proportion achieved remission. Overall 6/12-month secukinumab retention rates were 86%/74% and significantly higher in b/tsDMARD naïve patients at 12, but not 6 months ( Table 2 , Figure). Overall, crude 6- and 12-month DAPSA28≤4/DAS28CRP<2.6 were achieved by 13%/34% and 11%/39% of the patients, respectively.

All patients (n=1543 ) b/tsDMARD naïve (n=287 ) 1 prior b/tsDMARD (n=333 ) ≥2 prior b/tsDMARDs (n=923 ) p *
Age (years), mean (SD ) 52 (11) 49 (12.3) 51 (11) 53 (11) <0.001
Male, % 42% 49% 46% 39% 0.003
Years since diagnosis, mean (SD ) 9 (8) 7 (8) 8 (7) 10 (8) <0.001
Current smokers, % 19% 21% 22% 18% 0.23
CRP (mg/L), median (IQR ) 5 (2-12) 7 (2-19) 4 (2-8) 5 (2-11) <0.001
DAPSA28, median (IQR ) 26 (18-37) 28 (19-38) 22 (13-32) 27 (19-38) <0.001
DAS28CRP, median (IQR ) 4.2 (3.3-5.0) 4.4 (3.5-5.2) 3.8 (2.6-4.5) 4.2 (3.4-5.0) <0.001

*Comparisons across number of prior b/tsDMARD were done with ANOVA, Kruskal-Wallis or Chi-square test, as appropriate

Months All patients (n=1543) b/tsDMARD naïve (n=287) 1 prior b/tsDMARD (n=333) ≥2 prior b/tsDMARDs (n=923) p *
Secukinumab retention rate, % (95%CI) 6 86% (84-87%) 89% (86-93%) 85% (81-89%) 85% (82-87%) 0.11
12 74% (72-76%) 81% (76-86%) 76% (71-80%) 72% (69-75%) 0.006
DAPSA28≤4
 Crude 6 13% 25% 11% 11% <0.001
 LUNDEX 11% 22% 9% 9% <0.001
 Crude 12 11% 22% 11% 8% <0.001
 LUNDEX 7% 17% 7% 5% 0.001
DAS28CRP<2.6
 Crude 6 34% 51% 33% 30% <0.001
 LUNDEX 29% 45% 27% 24% <0.001
 Crude 12 39% 55% 41% 34% <0.001
 LUNDEX 26% 41% 27% 21% <0.001
DAPSA28 >4 and ≤14
 Crude 6 33% 42% 32% 30% 0.04
 LUNDEX 27% 37% 27% 25% 0.02
 Crude 12 35% 48% 36% 32% 0.009
 LUNDEX 24% 36% 24% 20% 0.004
DAS28CRP ≤3.2
 Crude 6 52% 69% 53% 47% <0.001
 LUNDEX 43% 61% 45% 38% <0.001
 Crude 12 55% 72% 55% 50% <0.001
 LUNDEX 37% 54% 37% 32% <0.001

*Comparisons across number of prior b/tsDMARDs were done with Kaplan-Meier with log-rank test or Chi-Square test, as appropriate


Conclusion: In this real-life study of 1543 patients with PsA in 13 European countries 12-month secukinumab retention was high, and significantly higher for b/tsDMARD naïve patients. Overall, a higher proportion of bionaïve than previous b/tsDMARD users achieved remission, regardless of remission criteria.


Acknowledgments: Novartis and IQVIA for supporting the EuroSpA RCN


Disclosure of Interests: Brigitte Michelsen Grant/research support from: Research support from Novartis, Consultant of: Consulting fees Novartis, Stylianos Georgiadis Grant/research support from: Novartis, Daniela Di Giuseppe: None declared, Anne Gitte Loft Grant/research support from: Novartis, Consultant of: AbbVie, MSD, Novartis, Pfizer and UCB, Speakers bureau: AbbVie, MSD, Novartis, Pfizer and UCB, Michael Nissen Grant/research support from: Abbvie, Consultant of: Novartis, Lilly, Abbvie, Celgene and Pfizer, Speakers bureau: Novartis, Lilly, Abbvie, Celgene and Pfizer, Florenzo Iannone Consultant of: Speaker and consulting fees from AbbVie, Eli Lilly, Novartis, Pfizer, Roche, Sanofi, UCB, MSD, Speakers bureau: Speaker and consulting fees from AbbVie, Eli Lilly, Novartis, Pfizer, Roche, Sanofi, UCB, MSD, Manuel Pombo-Suarez Consultant of: Janssen, Lilly, MSD and Sanofi., Speakers bureau: Janssen, Lilly, MSD and Sanofi., Heřman Mann: None declared, Ziga Rotar Consultant of: Speaker and consulting fees from Abbvie, Amgen, Biogen, Eli Lilly, Medis, MSD, Novartis, Pfizer, Roche, Sanofi., Speakers bureau: Speaker and consulting fees from Abbvie, Amgen, Biogen, Eli Lilly, Medis, MSD, Novartis, Pfizer, Roche, Sanofi., Kari Eklund Consultant of: Celgene, Lilly, Speakers bureau: Pfizer, Roche, Tore K. Kvien Grant/research support from: Received grants from Abbvie, Hospira/Pfizer, MSD and Roche (not relevant for this abstract)., Consultant of: Have received personal fees from Abbvie, Biogen, BMS, Celltrion, Eli Lily, Hospira/Pfizer, MSD, Novartis, Orion Pharma, Roche, Sandoz, UCB, Sanofi and Mylan (not relevant for this abstract)., Paid instructor for: Have received personal fees from Abbvie, Biogen, BMS, Celltrion, Eli Lily, Hospira/Pfizer, MSD, Novartis, Orion Pharma, Roche, Sandoz, UCB, Sanofi and Mylan (not relevant for this abstract)., Speakers bureau: Have received personal fees from Abbvie, Biogen, BMS, Celltrion, Eli Lily, Hospira/Pfizer, MSD, Novartis, Orion Pharma, Roche, Sandoz, UCB, Sanofi and Mylan (not relevant for this abstract)., Maria Jose Santos Speakers bureau: Novartis and Pfizer, Björn Gudbjornsson Speakers bureau: Novartis and Amgen, Catalin Codreanu Consultant of: Speaker and consulting fees from AbbVie, Accord Healthcare, Alfasigma, Egis, Eli Lilly, Ewopharma, Genesis, Mylan, Novartis, Pfizer, Roche, Sandoz, UCB, Speakers bureau: Speaker and consulting fees from AbbVie, Accord Healthcare, Alfasigma, Egis, Eli Lilly, Ewopharma, Genesis, Mylan, Novartis, Pfizer, Roche, Sandoz, UCB, Sema Yilmaz: None declared, Johan K Wallman Consultant of: AbbVie, Celgene, Eli Lilly, Novartis and UCB Pharma, Cecilie Heegaard Brahe Grant/research support from: Novartis, Burkhard Moeller: None declared, Ennio Giulio Favalli Consultant of: Consultant and/or speaker for BMS, Eli-Lilly, MSD, UCB, Pfizer, Sanofi-Genzyme, Novartis, and Abbvie, Speakers bureau: Consultant and/or speaker for BMS, Eli-Lilly, MSD, UCB, Pfizer, Sanofi-Genzyme, Novartis, and Abbvie, Carlos Sánchez-Piedra: None declared, Lucie Nekvindova: None declared, Matija Tomsic: None declared, Nina Trokovic: None declared, Eirik kristianslund: None declared, Helena Santos Speakers bureau: AbbVie, Eli-Lilly, Janssen, Pfizer, Novartis, Thorvardur Love: None declared, Ruxandra Ionescu Consultant of: Consulting fees from Abbvie, Eli-Lilly, Novartis, Pfizer, Roche, Sandoz, Speakers bureau: Consulting and speaker fees from Abbvie, Eli-Lilly, Novartis, Pfizer, Roche, Sandoz, Yavuz Pehlivan: None declared, Gareth T. Jones Grant/research support from: Pfizer, AbbVie, UCB, Celgene and GSK., Irene van der Horst-Bruinsma Grant/research support from: AbbVie, Novartis, Eli Lilly, Bristol-Myers Squibb, MSD, Pfizer, UCB Pharma, Consultant of: AbbVie, Novartis, Eli Lilly, Bristol-Myers Squibb, MSD, Pfizer, UCB Pharma, Lykke Midtbøll Ørnbjerg Grant/research support from: Novartis, Mikkel Ǿstergaard Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Merck, and Novartis, Consultant of: AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo Nordisk, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo Nordisk, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB, Merete L. Hetland Grant/research support from: BMS, MSD, AbbVie, Roche, Novartis, Biogen and Pfizer, Consultant of: Eli Lilly, Speakers bureau: Orion Pharma, Biogen, Pfizer, CellTrion, Merck and Samsung Bioepis

Citation: Ann Rheum Dis, volume 79, supplement 1, year 2020, page 1165
Session: Psoriatic arthritis (Poster Presentations)